Our Focus

The Colorado Chapter of the National Hemophilia Foundation (NHF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.


El Capítulo de Colorado de la Fundación Nacional de Hemofilia (NHF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento. Visite nuestra página en español aquí.

Have you or a loved one been personally impacted by current legislation surrounding medical policies? We'd love to connect with you! Please click on the button below to get involved with the Chapter's advocacy efforts.

News Articles

BioMarin recently shared findings from a phase 3 clinical trial (GENEr8-1) evaluating the presence of vector DNA in patients two years after they received a single dose of valoctocogene roxaparvovec, the company’s investigational hemophilia A gene therapy.

Novo Nordisk recently announced that the U.S.

As investigational hemophilia gene therapies move closer to regulatory authorization, community stakeholders have recognized the acute need for people with hemophilia (PWH) and healthcare professionals (HCPs) to be fully engaged in shared decision making (SDM).


1385 S. Colorado Blvd. Suite #610
Denver, CO 80222

© Colorado Chapter National Hemophilia Foundation 2022

Crafted by Firespring